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Abstract
Background: Elderly patients have been often excluded from or underrepresented in the study
populations of combination chemotherapy trials. The primary end point of this study was to
determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic
acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective
was to measure the time to disease progression and the survival time.
Methods: Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were
considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500
mg/m2 and folinic acid 250 mg/m2. All drugs were given intravenously on a day-1 schedule.
Results: A total of 42 elderly patients were enrolled. Median age was 73 years and all patients had
metastatic disease. The response rate according to RECIST criteria was 45.2% (95% CIs: 30%–56%)
with two complete responses, 17 partial responses, 13 stable diseases and 10 progressions, for an
overall tumor rate control of 76.2% (32 patients). Toxicity was generally mild and only three
patients discontinued treatment because of treatment related adverse events. The most common
treatment-related grade 3/4 adverse events were fatigue (7.1%), diarrhoea (4.8%), mucositis (2.4%),
neurotoxicity (2.4%) and neutropenia (4.8%). The median response duration was 5.3 months (95%
CIs: 2.13 – 7.34), the median time to disease progression was 5.0 months (95% CIs: 3.75 – 6.25)
and the median survival time was 9.0 months (95% CIs: 6.18 – 11.82).
Conclusion: OXALF represents an active and well-tolerated treatment modality for elderly
patients with locally advanced and metastatic gastric cancer.
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Gastric cancer is the fourth most frequent malignant dis-
ease and it is among the most common causes of cancer-
related death. Current epidemiological data indicate that
gastric cancer rarely occurs before the age of 40 years, its
incidence increases thereafter and peaks in the seventh
decade. Patients older than 65 years have been often
excluded from or underrepresented in the study popula-
tions of combination chemotherapy trials [1]. This demo-
graphic selection occurs in populations of gastric cancer
patients treated with combination chemotherapy regi-
mens. Demographic analysis of phase II and III chemo-
therapy trials show that only a minority of treated patients
were older than 65 years [2,3]. Consequently, there is
uncertainty about the type and the extent of systemic pal-
liative chemotherapy that should be offered to elderly
patients. In 2003, Graziano et al. [4] showed that the
weekly PLF (cisplatin/leucovorin/fluorouracil) chemo-
therapy may represent a valid and safety alternative for
elderly patients with advanced gastric cancer.
Oxaliplatin is an alkylating agent inhibiting DNA replica-
tion by forming adducts between two adjacent guanines
or guanine and adenine molecules. The adducts of oxali-
platin appear to be more effective than cisplatin adducts
with regard to the inhibition of DNA synthesis [5]. Many
studies are ongoing to test the oxaliplatin-based combina-
tions in non-colorectal gastrointestinal carcinomas and
other malignancies. Few studies have been addressed to
the analysis of oxaliplatin-based chemotherapy in
advanced gastric cancer [6-11]. The oxaliplatin dose-limit-
ing toxicity is a cumulative sensory peripheral neuropa-
thy. However, oxaliplatin may offer a more favourable
toxicity profile and higher activity compared to cisplatin.
We investigated in the present phase II study a weekly pro-
tocol with oxaliplatin, fluorouracil and folinic acid for
treating elderly patients with advanced gastric cancer.
Methods
Patients characteristics
Chemotherapy-naive pts with advanced gastric cancer [at
least one measurable lesion] aged 70 or older were consid-
ered eligible for study entry. Inclusion criteria consisted
of: ECOG performance status 0 or I, normal renal, liver,
bone marrow functions and measurable disease. The Katz
and Lawton scales were used to assess activities of daily
living [12]; the Katz activities of daily living (ADL) meas-
ures the ability to perform routine activities as bathing,
dressing, feeding oneself or getting into or out of bed,
chairs and vehicles. The Lawton instrumental activities of
daily living (IADL) measures more particular functions as
the ability to use the telephone, to shop, to handle
money, to prepare food or to perform other household
tasks. As an adjunct to general and cancer-specific diag-
nostic procedures, the comprehensive geriatric assessment
(CGA) was used at the study entry to identify and exclude
frail elderly patients. Frail elderly pts were excluded after
baseline geriatric assessment according to the following
criteria: age > 85 years, dependence in one or more activi-
ties of daily living, presence of three or more comorbidity
conditions and presence of one or more geriatric syn-
dromes. Classic geriatric syndromes which had to be
excluded before study inclusion were: dementia, delirium,
severe depression, frequent falls, neglect and/or abuse,
and spontaneous fractures [13]. Life expectancy ≥3
months, no concurrent uncontrolled medical illness, no
other malignancies. Patients were excluded if they had
National Cancer Institute common toxicity criteria grade
≥2 peripheral neuropathy. The protocol was approved by
each local institutional review board and written
informed consent was obtained from all participants.
Study design and dose modifications
Patients received weekly oxaliplatin 40 mg/m2 (90 min-
utes infusion), fluorouracil 500 mg/m2 (10 minutes
bolus) and folinic acid 250 mg/m2 (30 minutes infusion)
[OXALF]. All drugs were given intravenously on a day-1
schedule. Chemotherapy was given in an outpatient set-
ting. Antiemetic prophylaxis was given according to local
protocols. Most of patients received a pre-medication with
10 mg of metoclopramide without any post-medication.
According to treatment policy at each participating insti-
tution, the use of growth factors for white cells (G-CSF)
and eritropietin was allowed in the case of acute toxicity.
Full doses of the anticancer drug were given if granulocyte
count was >1500 microL and platelet count was >100000
microL. In the case of any grade 2 (G2) or more toxicity
except alopecia, chemotherapy was delayed a week and
then restarted after full recovery. Reduction of 25% in all
drugs dosing was applied for G3 non-hematological tox-
icity or for G4 hematologic toxicity in the previous cycle.
Patients with unsolved grade 2 or more toxicity after two
consecutive treatment delays, or experiencing grade 4
non-hematological toxicity except alopecia went off
study.
If peripheral neuropathy persisted between two following
cycles, the oxaliplatin dose in the next cycle had to
reduced by 50%. If pain was associated with peripheral
neuropathy 25% reduction in oxaliplatin dosing was
applied. If pain persisted between two following cycles,
oxaliplatin dose in the next cycle had to be reduced by
40% Treatment withdrawal was planned in the case of
persistent neuropathy with pain (G3) after the dose reduc-
tion.Page 2 of 7
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The primary end point of this study was to determine the
response rate and the toxicity of the weekly OXALF regi-
men in elderly patients with advanced gastric cancer. The
secondary objective was to measure the time to disease
progression and the survival time. The expected number
of patients for this study was calculated according to a
Simon optimal two-stage design. An interim analysis was
carried out when the first 18 assessable patients had been
recruited. If more than six responses [33.3%] were
observed, 24 additional patients were to be recruited; oth-
erwise, the study was to be terminated. The regimen was
considered sufficiently active to be submitted for further
evaluation if the response rate exceeded 30%. The time to
disease progression (TTP) was measured from the date of
registration to the date of documented disease progres-
sion or death. The survival time was measured from the
time of registration to the date of death resulting from any
cause.
Response and toxicity assessment
Responses were classified according to RECIST criteria
[14]. Computed tomography (CT) scans of measurable
lesions were carried out within 4 weeks before the start of
the treatment and at every disease restaging. Responses
were to be confirmed by subsequent CT scans 4 to 6 weeks
after the initial response documentation. Patients were
considered assessable for response if they had early dis-
ease progression or had received at least 8 cycles of treat-
ment with at least one tumor assessment.
Patients with responsive or stable disease received six
additional weekly cycles and they underwent a second
measurement at the end of the treatment program. Fol-
low-up controls were performed every 2 months thereaf-
ter. All patients had physical examination and blood
chemistries before each weekly administration of chemo-
therapy and toxicity was graded according to National
Cancer Institute common toxicity criteria.
Results
Response and survival
From October 2002 to April 2005, 42 elderly patients
entered on this study (median age, 73 years; range, 70–
81). Three patients did not complete eight weekly cycles
due to early progression (two patients), one patients
refused chemotherapy after grade III fatigue. Toxicities
reported in these three patients were included in the over-
all analysis of side-effects and they were considered as pro-
gressions in the intention-to-treat analysis of response.
The baseline clinico-pathologic characteristics of the 42
patients are reported in Table 1. At the end of the treat-
ment program, the best intention-to-treat overall response
rate in the 42 patients was 45.2% (95% CIs: 30–56%)
with two complete responses (4.7%), 17 partial responses
(40.5%), 13 stable diseases (31.0%) and 10 progressions
(23.8%), for an overall tumor control rate (responses plus
stabilizations) of 76.2% (32 patients) (Table 2).
The complete responses were observed in patients with
locoregional disease plus lymphnodal metastases and in
patients with liver metastases. Fifteen partial responses
were observed after eight weekly cycles and two other
patients with initial stable disease showed partial
response after 14 cycles.
In the whole group, the median follow-up was 14 months
[range 3.0–36 months]. The median response duration
was 5.3 months (95% CIs: 2,13 – 7,34), the median time
to disease progression was 5.0 months (95% CIs: 3,75 –
6,25) and the median survival time was 9.0 months (95%
CIs: 6,18 – 11,82) (Table 3). Time To Progression (TTP)
and Overall Survival (OS) were assessed by Kaplan-Meier-
Analysis shown in Figure 1 and 2.
Table 1: Patient characteristics
Characteristics No. of patients (%)
Total number 42 (100%)
Male/Female 26/16 (61.9/38.1)
Age (years)
median 73
range 70–81
Performance Status
ECOG 0 18 (42.8)
ECOG 1 24 (57.2)
Tumor differentiation
Well differentiated 10 (23.8)
Moderately differentiated 13 (30.9)
Poorly differentiated or undifferentiated 19 (45.3)
Locally advanced disease 10 (23.8)
Metastatic disease 32 (76.2)
Number of metastases
1 16 (38.2)
2 19 (45.2)
3+ 7 (16.6)
Sites of metastases
Liver 20 (47.6)
Peritoneum 9 (21.4)
Nodes 22 (52.4)
Local 15 (35.7)
Other 6 (14.3)
Prior adjuvant chemotherapy
None 35 (83.3)
Yes 7 (16.7)
Patients with metastases at the diagnosis 18 (42.8)
Number of cycles
Total 540
Median 12
Range 3–24Page 3 of 7
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42 patients received a total of 540 treatment cycles. The
median number of cycles administered was 12 (range, 3 to
24 cycles). The median cumulative doses in each patient
were 480 mg/m2 (range, 80 to 960 mg/m2) for oxaliplatin,
6,350 mg/m2 (range, 1,150 to 12,200 mg/m2) for 5-FU,
and 1,500 mg/m2 (range 250 to 3,000 mg/m2) for folinic
acid. Toxicity was generally mild and every grade of hae-
matologic and nonhaematologic toxicities per patient is
reported in Table 3. 42 patients were included in the safety
analysis. Toxicity was generally mild and only three
patients discontinued treatment because of treatment
related adverse events. Two refused for persistent grade 3
fatigue and the third discontinued for persistent grade 3
neurotoxicity. Overall, 3 patients (7.1%) experienced
grade 3 fatigue, 1 patient (2.4%) showed grade 3 neuro-
toxicity, 2 patients (4.8%) grade 3 neutropenia and
another (2.4%) grade 3 mucositis resolved after 1 week
delay. Two patients (4.8%) experienced one episode of
grade 3 diarrhea resolved after dose reduction. No other
grade 3–4 toxicities including peripheral neuropathy were
reported and no toxic deaths occurred. No patients
received G-CSF with both primary or secondary prophy-
lactic aim. Only two patients received G-CGF for persist-
ent grade 3 neutropenia. These two patients received G-
CSF only once for each. Grade 2 nausea and fatigue
resulted the commonest non-hematologic toxicity (both,
26.2% of patients). Other grade 2 non-hematologic toxic-
ities were: diarrhea (16.6%), mucositis (11.9%), hyperbi-
lirubinemia (7.1%) and neurotoxicity (11.9%). Two
patients (4.8%) reported grade 2 thrombocytopenia, no
patient reported grade 2 anemia. Overall, adverse events
were reversible and manageable with dose reduction, dose
delay or treatment interruption and with symptomatic
treatment. Twenty four (57.2%) patients received full
doses of all the drugs throughout the study. 5-fluorouracil
dose was reduced in 4 patients (9.5%), oxaliplatin dose
was reduced in 3 patients (7.1%), and the dose of both
agents was reduced in 11 patients (26.2%). The majority
of dose reductions were by one level (reduction to 75% of
starting dose of fluorouracil and/or of oxaliplatin). Only
three patients (7.1%) required a second dose reduction to
50% of starting dose of 5-fluorouracil and/or of oxalipla-
tin. Adverse events most commonly leading to dose reduc-
tion were fatigue and neurotoxicity. The incidence of dose
reductions was similar in the subgroups of male and
female patients. Only three patients (7.1%) reported a
toxicity-related withdrawal with median time to toxicity-
related withdrawal of 3.9 months (range: 1.8 – 6 months).
The median time to reduction was 2 months (range: 1.0 –
5.3) and the median time to first delay was 1.3 months
(range: 0.5 – 3) (Table 4).
The ADL and IADL scores showed non-significant
decrases after 8, 12 and 18 weeks of chemotherapy in
comparison to baseline scores.
Discussion
Gastric carcinoma frequently occurs in the 6th and 7th
decades and palliative chemotherapy is the ultimate treat-
ment in the majority of patients. The elderly population is
expanding and, from the early 1990s, one-quarter of
newly diagnosed gastric cancer patients are over 80 years
Table 2: Objective tumor response rates in advanced untreated 
elderly gastric cancer patients
Objective 
responses
Number 
(%)
Overall 
response rate
Overall tumor 
control rate
Complete Response 2 (4.7%) 19 (45.2%) 32 (76.2%)
Partial Response 17 (40.5%)
Stable Disease 13 (31.0%)
Disease Progression 10 (23.8%)
Table 3: Safety profile (according to NCI/CTC criteria)
Side effects Number of patients with toxicity (%)
Grade 1 Grade 2 Grade 3 Grade 4 All grades
Hematological
Anemia 4 (9.5%) 0 0 0 4 (9.6)
Leucopenia 4 (9.5%) 2 (4.8%) 0 0 6 (14.2%)
Neutropenia 1 (2.4%) 1 (2.4%) 2 (4.8%) 0 4 (9.6%)
Thrombocytopenia 2(4.8%) 2 (4.8%) 0 0 4 (9.6%)
Non-hematological
Nausea/Vomiting 5 (11.9%) 11 (26.2%) 0 0 16 (38.1%)
Mucositis 7 (16.7%) 5 (11.9%) 1 (2.4%) 0 13 (31.0%)
Neurotoxicity 8 (19.0%) 5 (11.9%) 1 (2.4%) 0 14 (33.3%)
Diarrhoea 8 (19.0%) 7 (16.6%) 2 (4.8%) 0 17 (40.4%)
Asthenia 15 (35.7%) 11 (26.2%) 3 (7.1%) 0 29 (69.0%)
Hyperbilirubinemia 1 (2.4%) 3 (7.1%) 0 0 4 (9.5%)
Anorexia 5 (11.9%) 3 (7.1%) 0 0 8 (19.0%)Page 4 of 7
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chemotherapy in elderly patients are almost lacking. To
the best of our knowledge, six phase II studies have been
published so far [16-21]. In five of these trials, chemother-
apy consisted of leucovorin-modulated 5-fluorouracil in
combination with cisplatin, epi-doxorubicin, etoposide
or mitomycin-C. A phase II study investigated the toxicity
profile and the activity of single-agent doxifluridine [21].
In general, the tumour control rate reported was promis-
ing and no toxic death was observed across all studies.
Unfortunately, these trials often enrolled patients with
concomitant illnesses, poor performance status and short
life expectancy and consequently, the results in term of
survival and safety were heterogeneous and, often, delud-
ing. More recently, Graziano et al [4] have reported the
results of a phase II trial investigating the weekly combi-
nation of cisplatin, 5-fluorouracil and folinic acid (PLF) in
a population advanced gastric cancer patients who were
older than 65 year. The regimen showed promising
tumour control rate and it was delivered to non-frail eld-
erly patients on outpatient basis. The non-haematological
toxicity profile was moderate and haematologic toxicity
was comparable to that usually observed in cisplatin-
based regimens. Filgrastim support was necessary in sev-
eral patients and it was maintained until the end of the
treatment program. Anaemia was recorded in 31 patients
whose haemoglobin concentrations declined to 10–12 g/
dl in 26 patients and to 8–9.9 g/dl in 15 patients.
Oxaliplatin may represent an intriguing alternative to cis-
platin with at least comparable activity, but a more
favourable global toxicity profile. So far, weekly and
biweekly FU/FA/oxaliplatin regimens have been mainly
explored in colorectal cancer patients with encouraging
efficacy data. More recently, weekly [10] and biweekly
oxaliplatin-based combinations have been also evaluated
in phase II studies of first- [6,7,9] and second- [22] line
chemotherapy for patients with advanced gastric cancer.
Based on these results, we planned a phase II study to
explore safety and efficacy of a weekly FU/FA/oxaliplatin
regimen in elderly (> 70 years old) advanced gastric cancer
patients. In the interesting Lordick's study [10] the
Figure 2
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Table 4: Toxicity-related treatment modifications
Treatment modifications No. of 
patients
%
Any dose reduction 18 42.8%
Any cycle delay 20 47.6%
Toxicity-related withdrawals 3 7.1%
Time to treatment modification Months Range
Median time to reduction 2.0 1.0–5.3
Median time to first delay 1.3 0.5–3
Median time to toxicity-related withdrawal 3.9 1.8–6.0Page 5 of 7
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given on days 1, 8, 15 and 22 of a 5-week cycle, while in
our study we decided to administer oxaliplatin at the
lower dose of 40 mg/m2 every week without any interrup-
tion. The dose-intensity of oxaliplatin in our study results
to be the same when compared with that calculated in the
lordick's study. Moreover, we chose to use a bolus 5-FU/
FA regimen because it was more simply to administer,
mostly in our elderly setting of patients, when compared
with the weekly 24-h infusional regimen. To the best of
our knowledge this is the first evaluation of this schedule
and it showed promising results. The overall response rate
in 42 assessable patients treated with OXALF regimen was
45.2%, including two CRs (4.7%) and 17 PRs (40.5%),
and it is comparable to the activity of other chemothera-
peutic regimens like FAMTX, ECF, ELF, and FOLFOX6
[25,26,22] and the weekly PLF schedule in elderly patients
[4]. Also, the median 5.0 months TTP and the median 9.0
months OS are similar to those reported after ECF, ELF,
CF, FAMTX, weekly PLF regimens [25,26]. As far toxicity is
concerned, the weekly OXALF regimen seems to cause less
haematological toxicity than the weekly PLF regimen, and
reduced need for haematopoietic growth factors. In gen-
eral, higher rates of neutropenia and leucopenia were
reported using other cisplatin and oxaliplatin-based pro-
tocols in advanced gastric cancer patients (38%, 29% and
36% WHO grade 3/4 neutropenia in ECF, FOLFOX 6 and
FOLFOX 4 regimens, respectively). [22-24]. The low inci-
dence of grade 3 toxicity and the absence of any grade 4
toxicity reported in the present study is very important for
the setting of elderly patients when compared with the
reported incidence of grade 3/4 toxicity in the above men-
tioned studies [11,22-24]. Moreover, the percent of
patients with dose-reduction of 5-FU alone, or oxaliplatin
alone or both was 26% (one patient every four) and most
of these dose reductions occurred late during the therapy
(Table 4), mostly after the first 8 cycles of the regimen.
This led us to give some toxicity only to responder-
patients avoiding to induce toxicity in non-responder
patients (equal or less than 8 cycles).
Conclusion
In conclusion, the weekly OXALF regimen seems a well-
tolerated treatment modality for elderly patients with
locally advanced and metastatic gastric cancer. Its promis-
ing activity deserves further evaluation in randomized
multicenter trials.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DS conceived of the study, participated in its design and
coordination and had an important role in the prepara-
tion of the manuscript. FG, VC and BV participated in the
design of the study and in the conduction of the study.
MD, ET, GC, AL, SG, BS, AR, MC, VV, SC and GT partici-
pated in the data base compilation and in the conduction
of the study. GT supervised all the steps of the study con-
duction. All authors read and approved the final manu-
script.
Acknowledgements
We thank Laura Rocci for her fruitful help in the conduction of the clinical 
trial.
References
1. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in
clinical trials for cancer drug registration: a 7-year experi-
ence by the US Food and Drug Administration.  J Clin Oncol
2004, 22:4626-31.
2. Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera
G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G,
Cellerino R, Catalano G: Intensive weekly chemotherapy for
advanced gastric cancer using fluorouracil, cisplatin, epi-dox-
orubicin, 6S-leucovorin, glutathione, and filgrastim: a report
from the Italian Group for the Study of Digestive Tract Can-
cer.  J Clin Oncol 1997, 11:3313-3319.
3. Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zani-
boni A, D'Angelo A, Salvagni S, Martignoni G, Beretta GD, Graziano
F, Berardi R, Franciosi V: High curative resection rate with
weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucov-
orin, glutathione, and filgastrim in patients with locally
advanced, unresectable gastric cancer: a report from the
Italian Group for the Study of Digestive Tract Cancer [GIS-
CAD].  Br J Cancer 2004, 8:1521-5.
4. Graziano F, Santini D, Testa E, Catalano V, Beretta GD, Mosconi S,
Tonini G, Lai V, Labianca R, Cascinu S: A phase II study of weekly
cisplatin, 6S-stereoisomer leucovorin and fluorouracil as
first-line chemotherapy for elderly patients with advanced
gastric cancer.  Br J Cancer 2003, 8:1428-32.
5. Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin:
mechanism of action and antineoplastic activity.  Semin Oncol
1998:4-12.
6. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S,
Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E: Phase II
trial of biweekly infusional fluorouracil, folinic acid, and oxali-
platin in patients with advanced gastric cancer.  J Clin Oncol
2004, 4:658-63.
7. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS,
Chang JY, Chung CY, Kao WY, Hsieh RK, Cheng AL: Phase II study
of weekly oxaliplatin and 24-h infusion of high-dose 5-fluor-
ouracil and folinic acid in the treatment of advanced gastric
cancer.  Br J Cancer 2004, 3:453-8.
8. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino
S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S,
De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G,
Bianco AR: A phase II study of biweekly oxaliplatin plus infu-
sional 5-fluorouracil and folinic acid [FOLFOX-4] as first-line
treatment of advanced gastric cancer patients.  Br J Cancer
2005, 9:1644-9.
9. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R,
Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de
Gramont A: Phase II study of oxaliplatin, fluorouracil, and foli-
nic acid in locally advanced or metastatic gastric cancer
patients.  J Clin Oncol 2002, 20:4543-4548.
10. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hen-
trich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M,
Seroneit T, Bredenkamp R, Duyster J, Peschel C: Phase II study of
weekly oxaliplatin plus infusional fluorouracil and folinic acid
[FUFOX regimen] as first-line treatment in metastatic gas-
tric cancer.  Br J Cancer 2005, 93:190-4.
11. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N,
Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates
J: Report of two protocol planned interim analyses in a ran-
domised multicentre phase III study comparing capecitabinePage 6 of 7
(page number not for citation purposes)
BMC Cancer 2006, 6:125 http://www.biomedcentral.com/1471-2407/6/125Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
with fluorouracil and oxaliplatin with cisplatin in patients
with advanced oesophagogastric cancer receiving ECF.  Br J
Cancer 2005, 92:1976-83.
12. Scott WK, Macera CA, Cornman CB, Sharpe PA: Functional health
status as a predictor of mortality in men and women over 65.
J Clin Epidemiol 1997, 50:291-296.
13. Balducci L, Yates J: General guidelines for management of older
patients with cancer.  Oncology 2000, 14:221-227.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubin-
stein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC,
Gwyther SG: New guidelines to evaluate the response to
treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Insti-
tute of the United States, National Cancer Institute of Can-
ada.  J Natl Cancer Inst 2000, 3:205-16.
15. Kranenbarg EK, Van de Velde CJ: Gastric cancer in the elderly.
Eur J Surg Oncol 1998, 5:384-90.
16. Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober
C, Link H, Meyer HJ, Lucke B: High dose folinic acid/etoposide/
5-fluorouracil in advanced gastric cancer: a phase II study in
elderly patients or patients with cardiac risk.  Invest New Drugs
1990, 8:65-70.
17. Cascinu S, Fedeli A, Catalano G: Etoposide, leucovorin 5-fluorou-
racil and interferon alpha-2b in elderly gastric cancer
patients: a pilot study.  Cancer Chemother Pharmacol 1994,
34:72-74.
18. Cascinu G, Catalano G: Intensive weekly chemotherapy for eld-
erly gastric cancer patients using 5-fluorouracil, cisplatin,
epi-doxorubicin, 6S-leucovorin and gluthatione with the sup-
port of G-CSF.  Tumori 1995, 81:32-35.
19. Di Bartolomeo M, Bajetta E, de Braud F, Bochicchio AM, Gebbia V,
Bozzetti F, Doci R, Bonfanti G, Cozzaglio L: Phase II study of the
etoposide, leucovorin and fluorouracil combination for
patients with advanced gastric cancer unsuitable for aggres-
sive chemotherapy.  Oncology 1995, 52:41-44.
20. Hartung G, Hofheinz R, Buchheidt D, Rost A, Brecht A, Forche K,
Schroder M, Wojatschek C, Fritze D, Hehlmann R, Queisser W:
Combination of bolus 5-fluorouracil, folinic acid and mito-
mycin-C in advanced gastric cancer: results of a phase II trial.
Onkologie 2000, 23:444-447.
21. Ikeda N, Shimada Y, Ohtsu A, Boku N, Tsuji Y, Saito H, Koizumi W,
Iwase H, Yoshida S, Fukuda H: A phase II study of doxifluridine
in elderly patients with advanced gastric cancer: the Japan
Clinical Oncology Group study [JCOG 9410].  Jpn J Clin Oncol
2002, 32:90-94.
22. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK: Phase
II study of oxaliplatin, 5-fluorouracil and leucovorin in previ-
ously platinum-treated patients with advanced gastric can-
cer.  Ann Oncol 2003, 14:383-387.
23. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P,
Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson
M, Hickish T: Long-term survival after epirubicin, cisplatin and
fluorouracil for gastric cancer: Results of a randomized trial.
Br J Cancer 1999, 80:269-272.
24. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino
S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S,
De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G,
Bianco AR: A phase II study of biweekly oxaliplatin plus infu-
sional 5-fluorouracil and folinic acid [FOLFOX-4] as first-line
treatment of advanced gastric cancer patients.  Br J Cancer
2005, 92:1644-9.
25. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK,
Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T,
O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M:
Randomized trial comparing epirubicin, cisplatin, and fluor-
ouracil versus fluorouracil, doxorubicin, and methotrexate
in advanced esophagogastric cancer.  J Clin Oncol 1997,
15:261-267.
26. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cut-
sem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H,
Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA:
Final results of a randomized phase III trial of sequential
high-dose methotrexate, fluorouracil, and doxorubicin ver-
sus etoposide, leucovorin, and fluorouracil versus infusional
fluorouracil and cisplatin in advanced gastric cancer: A trial
of the European Organization for Research and Treatment
of Cancer Gastrointestinal Tract Cancer Cooperative
Group.  J Clin Oncol 2000, 18:2648-2657.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/125/pre
pubPage 7 of 7
(page number not for citation purposes)
